JP2018503685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503685A5 JP2018503685A5 JP2017556784A JP2017556784A JP2018503685A5 JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5 JP 2017556784 A JP2017556784 A JP 2017556784A JP 2017556784 A JP2017556784 A JP 2017556784A JP 2018503685 A5 JP2018503685 A5 JP 2018503685A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- net
- inhibitor
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000003112 inhibitor Substances 0.000 claims 7
- 102000016911 Deoxyribonucleases Human genes 0.000 claims 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims 5
- 229940122298 Peptidyl arginine deiminase IV inhibitor Drugs 0.000 claims 5
- 239000003602 elastase inhibitor Substances 0.000 claims 5
- 108010077544 Chromatin Proteins 0.000 claims 4
- 229940122858 Elastase inhibitor Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 108010033040 Histones Proteins 0.000 claims 4
- 210000003483 chromatin Anatomy 0.000 claims 4
- 230000000593 degrading effect Effects 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 4
- BPWATVWOHQZVRP-NSHDSACASA-N Cl-Amidine Chemical group ClCC(=N)NCCC[C@@H](C(=O)N)NC(=O)C1=CC=CC=C1 BPWATVWOHQZVRP-NSHDSACASA-N 0.000 claims 3
- OLFDULIIJWCYCK-NSHDSACASA-N F-Amidine Chemical compound FCC(=N)NCCC[C@@H](C(=O)N)NC(=O)C1=CC=CC=C1 OLFDULIIJWCYCK-NSHDSACASA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 101100406797 Arabidopsis thaliana PAD4 gene Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 101150094373 Padi4 gene Proteins 0.000 claims 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105342P | 2015-01-20 | 2015-01-20 | |
| US62/105,342 | 2015-01-20 | ||
| PCT/US2016/013847 WO2016118476A1 (en) | 2015-01-20 | 2016-01-19 | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503685A JP2018503685A (ja) | 2018-02-08 |
| JP2018503685A5 true JP2018503685A5 (enExample) | 2019-02-21 |
Family
ID=56417634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556784A Pending JP2018503685A (ja) | 2015-01-20 | 2016-01-19 | 線維化を処置および予防するためのならびに創傷治癒を促進するための抗ｎｅｔ化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11400139B2 (enExample) |
| EP (2) | EP3247386A4 (enExample) |
| JP (1) | JP2018503685A (enExample) |
| CA (1) | CA2974369A1 (enExample) |
| WO (1) | WO2016118476A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3351263A1 (en) * | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| IL317968A (en) | 2017-08-18 | 2025-02-01 | Neutrolis Inc | Engineered deoxyribonuclease enzymes and their use in medicine |
| EP3761971A4 (en) * | 2018-03-09 | 2021-11-10 | The University of Memphis Research Foundation | FLAMMATION INHIBITION COMPOSITIONS AND METHODS |
| EP3813555A4 (en) * | 2018-06-29 | 2022-03-30 | Tets, Viktor, Veniaminovich | COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA |
| IL291111B2 (en) * | 2019-09-06 | 2024-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecn | Pharmaceutical composition for topical wound treatment |
| GB202012326D0 (en) * | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US6919320B1 (en) * | 1987-10-28 | 2005-07-19 | Wellstat Therapeutics Corporation | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| DE68928934T2 (de) | 1988-12-23 | 1999-08-05 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur herstellung von menschlicher dnase |
| DE3903672C1 (enExample) | 1989-02-08 | 1990-02-01 | Lohmann Gmbh & Co Kg | |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| US5539878A (en) | 1995-06-16 | 1996-07-23 | Elonex Technologies, Inc. | Parallel testing of CPU cache and instruction units |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| EP1156812A4 (en) | 1999-02-23 | 2004-09-29 | Isis Pharmaceuticals Inc | MULTIPARTICULAR FORMULATION |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| CA2555199A1 (en) | 2004-02-04 | 2005-08-18 | Yokohama City University | Peptidylarginine deiminase 4 inhibitor |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007056389A2 (en) | 2005-11-07 | 2007-05-18 | University Of South Carolina | Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases |
| WO2009121183A1 (en) | 2008-04-03 | 2009-10-08 | Kane Biotech Inc. | Dispersinbtm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof |
| KR20110063731A (ko) | 2008-06-16 | 2011-06-14 | 치라릭스 비.브이. | 펩티딜아르기닌 디이미나아제(ｐａｄ) 억제제 |
| US9642822B2 (en) * | 2011-05-27 | 2017-05-09 | Children's Medical Center Corporation | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| EP2775304A1 (en) * | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| CN105101989B (zh) * | 2013-04-09 | 2019-10-18 | 加贺谷伸治 | 白细胞的细胞外诱捕网形成的抑制剂 |
| GB201309180D0 (en) | 2013-05-21 | 2013-07-03 | Ucl Business Plc | Compounds and Their Uses |
| WO2014206856A1 (en) * | 2013-06-24 | 2014-12-31 | Dentsply Ih Ab | Medical device comprising collagen-vi |
-
2016
- 2016-01-19 WO PCT/US2016/013847 patent/WO2016118476A1/en not_active Ceased
- 2016-01-19 US US15/544,618 patent/US11400139B2/en active Active
- 2016-01-19 JP JP2017556784A patent/JP2018503685A/ja active Pending
- 2016-01-19 CA CA2974369A patent/CA2974369A1/en not_active Abandoned
- 2016-01-19 EP EP16740569.5A patent/EP3247386A4/en not_active Withdrawn
- 2016-01-19 EP EP20187049.0A patent/EP3797789B1/en active Active
-
2022
- 2022-06-24 US US17/848,998 patent/US20230190886A1/en not_active Abandoned
-
2025
- 2025-03-26 US US19/091,081 patent/US20250242000A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503685A5 (enExample) | ||
| Neckers et al. | Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development | |
| WO2018136264A9 (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| CN111868056A (zh) | 1,2,4-噁二唑类化合物及其制备方法和医药用途 | |
| JP2007523049A5 (enExample) | ||
| WO2006014353A3 (en) | Glycogen or polysaccharide storage disease treatment method | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| RU2018121036A (ru) | Комбинированная пре- и пробиотическая композиция | |
| WO2015095354A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| RU2018124487A (ru) | Лечение внутрипеченочного холестаза и родственных заболеваний печени | |
| JP2020507587A5 (enExample) | ||
| PH12020551905A1 (en) | C-mannoside compounds useful for the treatment of urinary tract infections | |
| Garrido et al. | Medical course and complications after lung transplantation | |
| JP2017536380A5 (enExample) | ||
| FI4009978T3 (fi) | Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon | |
| CA3249582A1 (en) | HSD17B13 2-SUBSTITUTE THIAZOLES INHIBITORS AND RELATED USES | |
| CL2024002462A1 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| JP2020523375A5 (enExample) | ||
| JP2019533715A5 (enExample) | ||
| JP2020527138A5 (enExample) | ||
| WO2020060779A3 (en) | Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle | |
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| CO5261512A1 (es) | Metodo y composiciones para el tratamiento de las enfermedades pulmonares | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 |